bevacizumab,panitumumab
roche,merck,amgen,takeda
['paradigm', 'serono']
interfering with the dna damage response (ddr) has the potential to improve the clinical paradigm in #oncology. our research is uncovering potential approaches to directly inhibit ddr pathways required for #cancer cell survival. #scienceofcancer #asco2023
Official Twitter for US Oncology business of EMD Serono a business of Merck KGaA Darmstadt, Germany. 
Intended for U.S. audience
CG: ➡️https://t.co/DN8q8OvEDb